Medicus Pharma Ltd. Launches SKNJCT-004 Phase 2 Clinical Study in UAE for Non-Invasive Basal Cell Carcinoma Treatment

Reuters

Yesterday

<a href="https://laohu8.com/S/MDCX">Medicus Pharma Ltd.</a> Launches SKNJCT-004 Phase 2 Clinical Study in UAE for Non-Invasive Basal Cell Carcinoma Treatment

Medicus Pharma Ltd. has announced the commencement of the SKNJCT-004 phase 2 clinical study aimed at non-invasively treating basal cell carcinoma $(BCC)$ of the skin. The study has begun recruiting participants at Cleveland Clinic Abu Dhabi and plans to include up to 36 subjects across multiple sites in the United Arab Emirates. This randomized, double-blind, placebo-controlled study will evaluate the efficacy of two dose levels of D-MNA compared to a placebo. Results of this study will be presented in the future. The company is also conducting a related study, SKNJCT-003, in the United States and Europe, which has shown promising interim results with over 60% clinical clearance.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Medicus Pharma Ltd. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1069891) on September 08, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/2565685295"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2565685295\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2565685295?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-08 19:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2565685295","market":"fut","top_or_hot":-1,"title":"Medicus Pharma Ltd. Launches SKNJCT-004 Phase 2 Clinical Study in UAE for Non-Invasive Basal Cell Carcinoma Treatment","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/MDCX\">Medicus Pharma Ltd.</a> Launches SKNJCT-004 Phase 2 Clinical Study in UAE for Non-Invasive Basal Cell Carcinoma Treatment\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/MDPLD\">Medicus Pharma</a> Ltd. has announced the commencement of the SKNJCT-004 phase 2 clinical study aimed at non-invasively treating basal cell carcinoma <a href=\"https://laohu8.com/S/BCC\">$(BCC)$</a> of the skin. The study has begun recruiting participants at Cleveland Clinic Abu Dhabi and plans to include up to 36 subjects across multiple sites in the United Arab Emirates. This randomized, double-blind, placebo-controlled study will evaluate the efficacy of two dose levels of D-MNA compared to a placebo. Results of this study will be presented in the future. The company is also conducting a related study, SKNJCT-003, in the United States and Europe, which has shown promising interim results with over 60% clinical clearance.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/MDPLF\">Medicus Pharma</a> Ltd. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1069891) on September 08, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Medicus Pharma Ltd. Launches SKNJCT-004 Phase 2 Clinical Study in UAE for Non-Invasive Basal Cell Carcinoma Treatment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMedicus Pharma Ltd. Launches SKNJCT-004 Phase 2 Clinical Study in UAE for Non-Invasive Basal Cell Carcinoma Treatment\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-09-08 19:30</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/MDCX\">Medicus Pharma Ltd.</a> Launches SKNJCT-004 Phase 2 Clinical Study in UAE for Non-Invasive Basal Cell Carcinoma Treatment\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/MDPLD\">Medicus Pharma</a> Ltd. has announced the commencement of the SKNJCT-004 phase 2 clinical study aimed at non-invasively treating basal cell carcinoma <a href=\"https://laohu8.com/S/BCC\">$(BCC)$</a> of the skin. The study has begun recruiting participants at Cleveland Clinic Abu Dhabi and plans to include up to 36 subjects across multiple sites in the United Arab Emirates. This randomized, double-blind, placebo-controlled study will evaluate the efficacy of two dose levels of D-MNA compared to a placebo. Results of this study will be presented in the future. The company is also conducting a related study, SKNJCT-003, in the United States and Europe, which has shown promising interim results with over 60% clinical clearance.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/MDPLF\">Medicus Pharma</a> Ltd. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1069891) on September 08, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250908:nNDL2K1Z6k:1","article_id":"2565685295","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2565685295","pubTimestamp":1757331050,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Medicus Pharma Ltd. has announced the commencement of the SKNJCT-004 phase 2 clinical study aimed at non-invasively treating basal cell carcinoma  of the skin. The study has begun recruiting participants at Cleveland Clinic Abu Dhabi and plans to include up to 36 subjects across multiple sites in the United Arab Emirates. This randomized, double-blind, placebo-controlled study will evaluate the efficacy of two dose levels of D-MNA compared to a placebo. Results of this study will be presented in the future. The company is also conducting a related study, SKNJCT-003, in the United States and Europe, which has shown promising interim results with over 60% clinical clearance.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Medicus Pharma L","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","MDCX":"Medicus Pharma Ltd."},"translate_title":"Medicus Pharma Ltd.在阿联酋启动SKNJCT-004治疗非侵袭性基底细胞癌的2期临床研究","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MDCX":0.9},"content_text":"Medicus Pharma Ltd. Launches SKNJCT-004 Phase 2 Clinical Study in UAE for Non-Invasive Basal Cell Carcinoma Treatment\n    \n\nMedicus Pharma Ltd. has announced the commencement of the SKNJCT-004 phase 2 clinical study aimed at non-invasively treating basal cell carcinoma $(BCC)$ of the skin. The study has begun recruiting participants at Cleveland Clinic Abu Dhabi and plans to include up to 36 subjects across multiple sites in the United Arab Emirates. This randomized, double-blind, placebo-controlled study will evaluate the efficacy of two dose levels of D-MNA compared to a placebo. Results of this study will be presented in the future. The company is also conducting a related study, SKNJCT-003, in the United States and Europe, which has shown promising interim results with over 60% clinical clearance.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Medicus Pharma Ltd. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1069891) on September 08, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}